Amgen (AMGN) and GSK (GSK) will be the latest drugmakers to sell their medicines on TrumpRx as the government-run direct-to-consumer platform for pharmaceutical products continues to expand, Fox Business reported.
With the addition of Amgen (AMGN) and GSK (GSK), a total of 54 prescription drugs from six pharma companies will be available on the site.
TrumpRx launched last month with Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and AstraZeneca (AZN) agreeing to sell their products on the site for cash-paying customers as part of President Donald Trump’s Most Favored Nation (MFN) drug pricing policy.
“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” said White House spokesman Kush Desai.
On TrumpRx, Amgen (AMGN) plans to offer Amjevita, an off-patent version of AbbVie’s (ABBV) arthritis therapy Humira, at $299 compared to its current U.S. list price of $1,484.
The California-based pharma giant will also offer a roughly 60% discount for its migraine therapy, Aimovig, and the cholesterol drug Repatha on the website.
Meanwhile, Incruse, a treatment from GSK (GSK) for chronic obstructive pulmonary disease, will be on sale at $159 with a 55% discount. The British drugmaker’s other prescription medicines, Arnuity, Relenza, and Anoro, will be available at discounts ranging from 10% to 51% on TrumpRx, according to the report.